Overview of the Legal Dispute
Pacira BioSciences, Inc. (NASDAQ: PCRX), a leader in innovative non-opioid pain management solutions, has taken a decisive step by filing a patent infringement lawsuit against The WhiteOak Group, Inc. and Qilu Pharmaceutical (Hainan) Co., Ltd. in the United States District Court for the District of Delaware. This action is specifically related to their best-selling product, EXPAREL® (bupivacaine liposome injectable suspension).
Background on EXPAREL®
EXPAREL is a groundbreaking long-acting local anesthetic designed to enhance postsurgical pain relief through infiltration and various nerve blocks. This innovative product is primarily utilized in surgical environments, providing significant advantages in pain management. Pacira's strong commitment to patient care is evident in the ongoing development and protection of its unique formulations.
Patent Protection and Strategy
The recent lawsuit aims to secure an injunction that would halt the manufacture, use, and sale of any generic versions of EXPAREL that may be developed by the defendants. This move aligns with the provisions of the Hatch Waxman Act, which allows for a 30-month stay on final FDA approval for generic applications post-filing of patent infringement suits.
Importance of Patent Rights for Innovation
Pacira holds 21 patents related to EXPAREL, which have been meticulously evaluated and granted after extensive scrutiny by the U.S. Patent and Trademark Office. These patents not only protect the unique formulation of EXPAREL but also safeguard the hefty investments in research and development made by the company. The strategic expiration dates of these patents range from 2041 to 2044, indicating the importance of sustaining exclusivity in the market for as long as possible.
Next Steps for the Competitors
For The WhiteOak Group and Qilu Pharmaceutical, introducing a generic version of EXPAREL would require navigating through significant legal and regulatory hurdles. They would need to present strong legal arguments against the enforced patents, establish commercial manufacturing capabilities, and demonstrate bioequivalence to attain FDA approval.
Our Confidence in EXPAREL
Pacira BioSciences is firm in its conviction regarding the strength and viability of its EXPAREL franchise. The company plans to vigorously defend its intellectual property rights while continuing to innovate within the non-opioid pain management arena.
Innovative Products and Future Directions
In addition to EXPAREL, Pacira is making strides with other non-opioid treatments, including ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) and the iovera° device, which provides immediate pain relief without the use of medications. The company is also pursuing the development of PCRX-201, a new gene therapy aimed at addressing significant health challenges, including osteoarthritis.
Commitment to Patient-Centered Care
Pacira's commitment to improving patient outcomes goes beyond its products. The company continuously seeks to establish new opportunities and avenues for treatment, ensuring that advancements in healthcare translate effectively into real-world benefits for patients. Their focus remains on non-opioid alternatives, aligning with a broader public health initiative to reduce opioid dependency.
Contact Information
If you have inquiries about Pacira BioSciences or its products, the company's investor contact is Susan Mesco at (973) 451-4030. For media inquiries, please reach out to Kim Hamilton at (973) 254-4644.
Frequently Asked Questions
What is the significance of Pacira's lawsuit?
The lawsuit is crucial for Pacira as it seeks to protect its intellectual property rights regarding EXPAREL, ensuring the integrity of its product in the face of competition.
How does EXPAREL work?
EXPAREL utilizes a unique formulation of bupivacaine delivered through multivesicular liposomes to provide prolonged pain relief post-surgically.
What is the Hatch Waxman Act?
The Hatch Waxman Act allows for a 30-month stay on FDA approvals for generics when a patent lawsuit is filed, assisting original drug developers in protecting their innovations.
What other products does Pacira offer?
In addition to EXPAREL, Pacira markets ZILRETTA and the iovera° device, both designed for effective pain management without opioid involvement.
How can investors stay updated on Pacira?
Investors can reach out to the investor relations contact at Pacira or visit their website for the latest information regarding company developments and product offerings.
